Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lebrikizumab (Primary)
Indications Atopic dermatitis; Eczema
Focus Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

12 Jun 2020 According to an Eli Lilly and Company media release, data from this study was presented at the American Academy of Dermatology 2020 Annual Meeting.
12 Jun 2020 Results published in the Eli Lilly and Company Media Release
26 Feb 2020 Results assessing efficacy and safety of lebrikizumab in adults with moderate to severe atopic dermatitis, published in the JAMA Dermatology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com